IL314852A - Salt and crystal form of dipeptidyl peptidase inhibitor compound - Google Patents

Salt and crystal form of dipeptidyl peptidase inhibitor compound

Info

Publication number
IL314852A
IL314852A IL314852A IL31485224A IL314852A IL 314852 A IL314852 A IL 314852A IL 314852 A IL314852 A IL 314852A IL 31485224 A IL31485224 A IL 31485224A IL 314852 A IL314852 A IL 314852A
Authority
IL
Israel
Prior art keywords
crystalline form
formula
compound
present
provides
Prior art date
Application number
IL314852A
Other languages
English (en)
Hebrew (he)
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of IL314852A publication Critical patent/IL314852A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL314852A 2022-02-22 2023-02-21 Salt and crystal form of dipeptidyl peptidase inhibitor compound IL314852A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210160862 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (1)

Publication Number Publication Date
IL314852A true IL314852A (en) 2024-10-01

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314852A IL314852A (en) 2022-02-22 2023-02-21 Salt and crystal form of dipeptidyl peptidase inhibitor compound

Country Status (13)

Country Link
US (1) US20250188067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4484414A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508792A (cg-RX-API-DMAC7.html)
KR (1) KR20240153351A (cg-RX-API-DMAC7.html)
CN (1) CN118660873A (cg-RX-API-DMAC7.html)
AU (1) AU2023225835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002490A1 (cg-RX-API-DMAC7.html)
IL (1) IL314852A (cg-RX-API-DMAC7.html)
MX (1) MX2024010180A (cg-RX-API-DMAC7.html)
TW (1) TW202342466A (cg-RX-API-DMAC7.html)
WO (1) WO2023160542A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407225B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物

Also Published As

Publication number Publication date
EP4484414A1 (en) 2025-01-01
TW202342466A (zh) 2023-11-01
AU2023225835A1 (en) 2024-10-03
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
ZA202407225B (en) 2025-12-17
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22
JP2025508792A (ja) 2025-04-10
US20250188067A1 (en) 2025-06-12
WO2023160542A1 (zh) 2023-08-31
EP4484414A4 (en) 2026-01-28
CN118660873A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
US20250188067A1 (en) Salt and crystal form of dipeptidyl peptidase inhibitor compound
EP4484424A1 (en) Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
KR102788829B1 (ko) 야누스 키나제 억제제의 결정질 형태
WO2016178416A1 (ja) ウラシル化合物の新規結晶
EP3924355B1 (en) COMPOUND OF PYRIMIDINYL-3,8-DIAZABICYCLO [3.2.1] CRYSTALLINE OCTANYLMETHANONE AND ITS USE
EP3286190B1 (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)
KR101557832B1 (ko) (r)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
CA2413087C (en) Suplatast tosilate crystals
CN116041324B (zh) 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
EA053095B1 (ru) Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы
JP7187733B2 (ja) オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶
WO2007080362A1 (en) Pharmaceutically acceptable co-crystalline forms of sildenafil
US10703760B2 (en) Morphic forms of marizomib and uses thereof
US7824710B2 (en) Crystalline and stable form of andolast
US20190062307A1 (en) Deuterium-substituted quinoline derivatives
EA051477B1 (ru) Полиморф ингибитора дипептидилпептидазы 1, способ его получения и применение
WO2026017797A1 (en) Crystalline forms
CN116396305A (zh) 一种稠环衍生物的晶型、其制备方法及其应用
AU2022412842A1 (en) Novel acid addition salt and crystalline form of (2r,3s)-2-(3-(4,5-dichloro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
JP2007332032A (ja) 医薬結晶化合物
HK1249906B (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)
HK1109629A (en) A new crystalline and stable form of andolast